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Objective:  To investigate the cost-effectiveness of a modified form of 
cognitive behaviour therapy for recurrent non-cardiac chest pain. 
 
Methods:   We tested the effectiveness and cost-effectiveness of a 
modified form of cognitive behaviour therapy for chest pain (CBT-CP)(4-10 
sessions) in patients who attended cardiology clinics or emergency medical 
services repeatedly. Patients were randomised using a remote web-based 
system to CBT-CP or to standard care in the clinic. Assessments were made 
at baseline and at six and 12 months. The primary outcome was the change 
in the Health Anxiety Inventory score at six months. Other clinical 
measures, social functioning, quality of life, and costs of services were also 
recorded.  
 
 3 
 Results: 68 patients were randomised with low attrition rates at 6 and 12 
months with 81% of all possible assessments completed at 6 and 12 
months. Although there were no significant group differences between any 
of the outcome measures at either 6 or 12 months, patients receiving CBT-
CP had between two and three times fewer hospital bed days, outpatient 
appointments, and A&E attendances than those allocated to standard care 
and total costs per patient were £1496.49 lower, though the differences in 
costs were not significant. There was a small non-significant gain in quality 
adjusted life years (QALY's) in those allocated to CBT-CP compared with 
standard care (0.76 vs 0.74).  
 
Conclusions:  It is concluded that CBT-CP in the context of current hospital 
structures is not a viable treatment, but is worthy of further research as a 
potentially cost-effective treatment for non-cardiac chest pain. 
 
Trial registration:  ISRCTN 14711101 
 
Introduction 
 
Non-cardiac chest pain has the status of a medical diagnosis (ICD-10, 
R07.89) but shares this diagnosis with 20 other synonyms under the general 
heading of 'other chest pain' and is highly heterogeneous.  It includes a 
range of disorders including a general description only (non cardiac chest 
pain, atypical chest pain, non-specific chest pain), muscular tension (chest 
pain, musculoskeletal, chest pain, tightness, musculoskeletal chest pain), 
pain generated in other structures apart from the heart (sternal chest pain, 
chest wall pain, localised chest pain) and pain related to exertion 
(exertional chest pain, chest pain on exertion).  None of the diagnostic 
labels include any indication of a psychological component, even though 
there is abundant literature on psychological interventions for the 
condition1-3. 
 
Despite this lack of attribution, it is suspected that a substantial proportion 
of patients with non cardiac chest pain have psychological causes, or at 
least can be treated appropriately using psychological means. Possible 
causes include excessive health anxiety (termed illness anxiety in the DSM-
5 classification4), one or more variants of somatic symptom disorder, the 
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former diagnosis of hypochondriasis, and obsessive compulsive disorder. 
But because these diagnoses are given by mental health professionals, not 
by the physicians who make the diagnosis of non-cardiac chest pain, they 
are seldom recorded in practice. Health anxiety has recently been 
associated with a future ischaemic heart disease in the general population 
over 12 years even when known risk factors for cardiovascular disease are 
controlled for5. Health anxiety is also associated with adverse cardiac 
events in those who had myocardial infarction over the subsequent four 
years6. Therefore health anxiety may be important to recognise and treat in 
its own right because of poor cardiac outcomes. Thus, despite good 
evidence that most of the people who present with non-cardiac chest pain 
do not have heart disease7-8  we do not know how many have physical 
causes or precipitants and how many have psychological ones.  
 
Previous work has suggested that many of these patients can be treated 
successfully in a relatively short number of sessions with different forms of 
cognitive behaviour therapy (CBT). Two findings gleaned from randomised 
trials are noteworthy. The effects of treatment are relatively modest, 
rapidly achieved but short-lasting (with maximal benefit at 3m and usually 
lost by 6 months), and the number of patients who are potentially eligible 
for trial inclusion far exceeds those who actually take part9.  In planning a 
new trial on the basis of new evidence of a modified form of treatment10 
we therefore wished to maximise the recruitment rate, have a longer 
period of follow-up, and to try and select patients with psychological causes 
for their chest pain.  
 
Method 
 
The design was a simple two-treatment parallel design with equal 
allocation to either an adapted form of cognitive behaviour therapy for 
chest pain (CBT-CP) or to standard care in the relevant NHS services. The 
randomisation was carried out by an independent Clinical Trials Unit 
(Health Services Unit, CHaRT, University of Aberdeen) with equal allocation 
to CBT and ST, with initial help given from Open-CDMS, a similar 
independent unit. 
 
Inclusion and exclusion criteria 
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Inclusion criteria were (a) significant chest pain on at least two separate 
occasions in the past year in which no significant pathology explaining the 
symptoms was found, (b) signed consent to take part in the study, (c) age 
between 18 and 75. The exclusion criteria were (a) under active psychiatric 
care, (b) having received a prescription of a new psychoactive drug within 
the previous two months, (c) receiving, or on waiting list for, a formal 
psychological treatment. Those who were currently stable and on regular 
psychoactive medication (for more than 2 months) were eligible for the 
study. By seeing patients who had presented more than once in the past 
year it was hoped that a more resistant cohort would be recruited with less 
likelihood of nonspecific improvement. 
 
Assessments 
 
It was not clear which psychopathology would be most prominent in these 
patients, but because health anxiety had been found to be a common 
feature in many patients presenting to cardiology clinics10 the change in 
scores on the short form of the Health Anxiety Inventory11 was chosen as 
the primary outcome.  
 
A more specific outcome, but not one that had previously been validated, 
was the Health Anxiety Questionnaire12 adapted for Chest Pain (Lucock & 
Morley Health Anxiety Questionnaire – Chest Pain (LMHAQ-CP), which 
included special questions on chest pain agreed with the original authors. 
The original Health Anxiety Questionnaire was also being used as the 
primary outcome in a parallel study in Christchurch, New Zealand, and so it 
was felt important to be included. Other assessments included self-
completed analog ratings of both the frequency and severity of chest pain 
and discomfort developed with the aid of a patient (Inskip 
Scale)(Appendix), self-ratings of generalised anxiety and depression (using 
the Hospital Anxiety and Depression Scale (HADS scale)13, and social 
functioning using the Social Functioning Questionnaire (SFQ)14. The 
Schedule for Evaluating Persistent Symptoms (SEPS)15, that had been found 
in preliminary studies to be an accurate measure of medically unexplained 
symptoms, was also included.  Quality of life was recorded using the EQ-5D 
scale16 at six months and one year. In addition, all health service related 
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costs were recorded using the ADSUS (Adult Service User Schedule)17 in the 
6 months before randomisation and at 6 month intervals subsequently until 
one year. Using these data the overall costs for patients in the two arms of 
the trial were compared as well as major cost items such as in-patient care. 
 
Target number of participants 
 
From previous work with the Health Anxiety Inventory we calculated that a 
difference between the scores of 4 between two groups at follow-up is 
clinically significant. Using data from an unrelated randomised controlled 
trial of CBT in health anxiety18 we demonstrated a significant benefit 
between CBT and control with a sample of 49 patients. In this study with a 
standard deviation for the change of HAI at 1 year as 6.0 a sample size of 96 
patients would have 90 % power to demonstrate significance at the two-
sided 5 % significance level. 
 
Ethics and consent 
 
All patients recruited to the study read a brief information sheet initially 
and randomisation discussed with clinical staff involved in their care. Those 
that consented were then seen by a research assistant, who gave each 
person a full participant information sheet and explained the study. If, after 
full assessment and explanation, patients agreed to take part, a signed 
declaration of informed consent was completed. The study was approved 
by the NRES (Ethical) Committee East Midlands, Northampton, UK 
(11/EM/0376). 
 
Procedure 
 
Initially the trial was confined to Kings Mill Hospital, North Nottinghamshire 
but because of poor recruitment was subsequently extended to The Royal 
Berkshire Hospital in Reading and The Hillingdon Hospital in Middlesex 
after appropriate ethical amendments.  
 
Patients satisfying the criteria for inclusion and lacking exclusion criteria 
who presented with chest pain to either cardiology clinics, acute medicine 
and/or accident and emergency departments at the three hospitals above 
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were considered for the study. Two other centres were included by 
agreement but the lack of a local principal investigator prevented 
recruitment from ever starting. The procedures for the chest pain pathway 
are not the same at these three hospitals but are still likely to be 
representative of the UK as in most hospitals there is no standard pathway 
for the assessment of non-cardiac chest pain unless rapid access chest pain 
clinics are available. 
 
Avoidance of bias 
 
Concern has been expressed that bias may have been present in previous 
trials because single-blind assessment was prevented by trial protocols9. 
Because of this all assessors made assessments without any discussion of 
treatment and if for any reason allocation was disclosed at interview a 
different researcher was involved in future assessments.  
 
Randomisation 
 
Patients identified as eligible for the trial by cardiology and accident and 
emergency staff, and willing to take part, were first assessed by an 
independent research assistant. After baseline assessment all ratings and 
demographic details are recorded on a secure on-line data base, initially 
Open-CDMS in London and from 2014, CHaRT in the Health Services 
Research Unit, University of Aberdeen. Patients were then allocated to 
either CBT-CP or standard care in permuted stacked blocks and stratified by 
study centre. The allocated treatment was then passed to the trial 
coordinator (SC) who, if the patient was allocated to CBT-CP, informed the 
next available therapist at the centre concerned and then the patient, GP 
and consultant. Patients allocated to standard care are informed by letter 
or phone call and the GP and hospital team also notified. Follow up 
assessments were carried out by research assistants who were ignorant of 
the original allocation after 6 and 12 months.  
 
Experimental interventions 
 
 CBT-CP (CBT for Chest Pain) 
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This was given by nursing staff and psychologists trained and supervised by 
HT. The procedure initially was a modification of cognitive behaviour 
therapy for health anxiety (CBT-HA)19 and its essential features were linked 
to health anxiety, including a formulation made for a recent episode of 
chest pain, assessment of the behaviours that appeared to be maintaining 
the pain, building up a model of the cognitive theory of emotion with 
illustrations where necessary of the nature of symptoms, and using the 
patient's strengths in finding alternative strategies of dealing with chest 
pain.  It was also felt important to check that any gains made were 
consolidated and, where they were not, to emphasise techniques of relapse 
prevention before finishing treatment, not least because of previous 
evidence that gains in other studies were not maintained9. When it was 
found that health anxiety was not a prominent feature in the presentation 
the focus shifted to examining other underlying fears and worries and 
changing the format of sessions. These included anxieties about 
vulnerability to assault, extreme exhaustion after chest pain, and the fear 
that some important pathology would be missed if assessment was not 
made urgently. These often only became apparent later in therapy. 
According to our planned protocol20 between 4 and 10 sessions were 
offered but some flexibility was allowed as in our previous study up to 14 
sessions were needed in more complex cases10 .  
 
Standard care 
 
No change was made to the form of care given to the patients allocated to 
this group in either their primary or secondary care settings. Thus, at 
various times care involved appropriate testing, explanation of findings, 
reassurance and the opportunity for the patient to ask questions about the 
symptoms and the test results. These interventions were made by the 
relevant clinicians and not influenced by the trial investigators. GP’s were 
informed about the allocation of each patient after randomisation but 
received no further information subsequently.  
 
 
Primary and secondary outcomes 
 
The primary outcome was the reduction in scores on the Health Anxiety 
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Inventory between baseline and 6 months.  Although previous studies have 
recorded outcomes at 3 months we did not think all psychological 
treatment would have been completed by then so did not record at this 
time point. Secondary outcomes were (i) the reduction in visual analog 
scores of frequency and intensity of chest pain, (ii) reduction in LMHAQCP 
scores, (iii) reduction in the total SEPS score, (between baseline and 6 
months and one year, (ii) the number of attendances at Accident & 
Emergency Departments after 6 months and one year, (iii) total health 
service costs in primary and secondary care at 6 and 12 months, (iv) 
reduction in generalised anxiety symptoms (on the HADS-Anxiety Scale 
after 6 months and 1 year, (v) reduction in depressive symptoms on the 
HADS-Depression Scale at the same time points, and (vi) change in mean 
LMHAQCP scores from baseline after one year. 
 
Statistical Analysis 
 
All analyses were by intention to treat, analysed as randomised. The 
primary analysis compared mean change scores of the Health Anxiety 
Inventory scale from the baseline to 6 months between the treatment and 
control groups. Multilevel modelling (MLM)was used to estimate and test 
differences of mean change scores between the two comparison groups 
adjustment for baseline score21,22. Centre influence on treatment effect 
estimates was initially controlled during modelling but results without 
adjusting centre influence was presented given the small patient samples23.  
Missing values were imputed under Missing at Random assumption with 
REALCOME software24. MLM was also performed with observed only data 
to check the robustness of treatment effect estimates sensitive to 
missingness. Analyses of secondary outcomes followed the same analytic 
procedure and statistical approaches. Stata 14 was used for data analysis. 
 
Economic evaluation 
 
The economic evaluation adopted a health and social care perspective by 
collecting all the service use data over the period of follow-up, and so 
allowing the total cost of the services used by each study participant to be 
summed. These costs were taken together with the cost of the CBT to 
generate the average costs for each randomised group. The costs were 
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compared using standard t-tests, recommended for economic analysis as 
they allow for analysis of mean costs without transformation. The 
robustness of this approach was checked through the calculation of 
bootstrapped confidence intervals25,26. A limited cost-effectiveness analysis 
was also performed where the costs in the CBT-CP and ST groups were 
compared alongside the difference in QALYs derived from the EQ-5D 
scores.  
 
Results 
 
Only 68 patients (47 M; 21 F) were recruited to the study in the 30 months 
between July 2012 and December 2014; this included a 9 month extension.   
As the study was underpowered greatly, significant group differences were 
not expected nor found. 34 patients each were randomised to the two 
groups. Attrition rates were low, with only 26 (19%) of the 136 possible 
follow-up points missing (Figure). The mean number of treatment sessions 
in the CBT-CP group was 5.7(range 0-15), carried out over a mean period of 
14.3 weeks (sd 8.78). The longer period of treatment was sometimes 
necessary as there was considerable comorbidity. In the CBT-CP group 12 
(35%) of the patients had other pathology (five with previous cardiac 
disease independent of present symptomatology, two with gastrointestinal 
pathology probably linked to the chest pain (irritable bowel syndrome and 
gastric reflux), two with other psychopathology (chronic fatigue syndrome 
and post-traumatic stress disorder), and three with sexual health disorders.  
One patient disclosed the nature of the allocation to the research worker 
during follow-up. As a consequence, all further assessments were made by 
an independent researcher.   
  
 
The primary outcome was the change in HAI scores at six months. This was  
probably an error in selection. Most patients (63%) did not have HAI Scores 
at or above the pathological level of 20 (Table 1). At 6 months these scores 
showed greater improvement in the standard care arm (3.29, 95%CI: -5.63, -
0.95) than the CBT-CP arm (2.35, 95%CI: -4.58, -0.12), but the opposite effect 
was shown at 12 months (SC 4.21(95%CI: (-6.73, -1.69); CBT-CP 4.97(95%CI: (-
7.41, -2.54)).   
 
 11 
  
 
Although none of the treatment differences were significant (Table 2) it was 
notable that for almost every measure there was greater improvement in 
the CBT-CP group then for standard care at 12 months compared with 6 
months (Table 2). The LMHAQCP showed the greatest differences between 
CBT-CP and standard care at 12m (mean difference 4.36, 95%CI: -9.60, 0.87; 
P=0.1). 
 
Economic analysis 
 
Economic data were obtained on all patients at baseline , 85% at 6 months 
(85%) and 76% at 12 months (76%) follow-up. For full analysis 50 of the 68 
patients were used (74%). 
 
Over 12 months there was an observable difference in the use of hospital 
services between randomised groups; on average participants in the CBT 
group had fewer nights as inpatients and less than half as many outpatient 
appointments and A&E attendances as those in the standard care group 
(Table 3). The use of community services was similar in both groups. The 
CBT-CP intervention cost on average, £480 per participant. The between 
group differences in hospital service use is reflected in the cost of these 
services over follow-up. The CBT –CP group used on average £1771.52 less 
in hospital services, which more than covered the cost of the CBT-CP (Table 
4). Thus the average cost of all services over follow-up was £2235.53 in the 
CBT-CP group compared to £3732.02 in the standard care group. The 
difference was not statistically significant, largely because of a wide scatter 
of scores (p=0.798).  
  
 
The utility scores, as measured using the EQ5D were broadly similar and 
improved over time in both groups. There was a small and non-significant 
higher QALY over follow-up in the CBT group (0.76 QALYs) compared to the 
TAU group (0.74 QALYs) (Table 5). Considering costs and outcomes 
together, the CBT-CP intervention resulted in lower overall costs and better 
outcomes.  
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Discussion 
 
The most unusual feature of this trial is that, despite addressing a very 
common problem in clinical practice, only 68 patients were recruited from 
three sites over a 30 month period. We are not in a position to determine 
why the recruitment rate was so low and are not sure how many eligible 
patients did not take part, but from the partial data we collected only about 
20% of those who could have taken part, did so. In spite of this, those that 
did take part were adherent to treatment and had low levels of drop-out, 
so it was clearly the recruitment uptake that was the main problem (and 
the possible reasons for this are discussed further in the supplement to this 
paper). As the trend for improvement was in favour of CBT-CP for almost all 
measures at 12 months, if the study had been adequately powered the 
results might have been different.   
Our study represents the first trial of psychological treatment for non-
cardiac chest pain to include a robust economic evaluation.  The reduction 
in frequency of attendance at accident and emergency department, in 
outpatient clinics, and in use of bed days, were notable in the CBT-CP group 
and illustrate the reduced demand on services that follows treatment. 
Between group differences in costs were not significant, but the study was 
not designed with sufficient statistical power to detect them.  
 
Guidance for future research on this subject 
 
During the course of this study it has been very apparent that the way in 
which services are currently configured do not allow psychological 
treatments to be adequately assessed. This is clear from previous studies; 
high levels of failure to recruit eligible patients and high drop-out rates are 
prominent. A recent Cochrane review of psychological treatment for non-
cardiac chest pain examined the effect of psychological interventions in a 
total of 17 randomised controlled trials involving 1006 participants. Despite 
these many studies the overall conclusion is tentative and of limited benefit 
to clinicians;  ‘this review suggests a modest to moderate benefits of 
psychological interventions, particularly those using a cognitive behavioural 
framework, which was largely restricted to the first three months after the 
intervention’ 9. Just over half of eligible patients agreed to take part and in 
the five largest studies, including 331 patients, the drop-out rates ranged 
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between 28% and 57%.   
 
The previous studies have taken place over a period of more than 20 years 
and, not surprisingly, do not appear to have influenced practice except in a 
few centres.  It is also of some concern that, when benefit has been shown, 
it is of such limited duration, and could be deemed not worthy of service 
adoption.  The results of the COPIC study should be seen in this context. 
Despite its inability to recruit an adequate number of patients, the results 
using CBT-CP suggest that the intervention was adding more than standard 
cognitive behaviour therapy, with economic benefits maintained over one 
year.   
 
It is relevant that the supervisor of all the therapists in the study (HT) was a 
medically qualified doctor who had been employed in both primary and 
secondary care as well as having well developed skills in cognitive 
behaviour therapy.  This allowed her to detect several other additional 
pathologies (oesophageal reflux, chronic fatigue syndrome, post-traumatic 
stress disorder), contributing to the non-cardiac chest pain, that would 
probably not have been detected by a psychologist or other therapist just 
trained in CBT. It also complicated the length of the CBT-CP treatment so 
that most patients completed their treatment between 3 and 6 months 
after randomisation. This may have been a factor in both the delayed 
improvement at 6 months and better outcomes at 12 months, so setting 
this study apart from previous ones.  
 
This combined medical and psychological morbidity may have been more 
pronounced in the population of repeat attenders in the COPIC study but is 
highly relevant both to continuing research in this area and to service 
provision. Future studies have to take into account several factors. Non-
cardiac chest pain is inadequately treated at present and is associated with 
considerable morbidity, significant costs and poor outcomes27-28.  As the 
costs of care for physical disease are so much greater than those for the 
management of psychological problems, a marked saving could be made in 
a successful treatment programme.  
In 1997 Mayou and his colleagues completed one of the early trials of CBT 
for non-cardiac chest pain in patients attending a cardiac clinic29.  Their 
findings are of interest because they adumbrated much of subsequent 
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publication on the subject.  After careful screening of 90 subjects they 
found 56 to be eligible but of these only 37 took part, with 60% completing 
all assessments at 12 months.  This reluctance, according to the authors, 
‘reflected the particular problems of introducing a psychological treatment 
to patients who had been referred to cardiologists with presumptive 
cardiac diagnoses’.   This ‘abrupt change in clinical direction’ was clearly not 
acceptable to many patients.  Mills and Mayou30 followed this subject up 
shortly afterwards in a series of editorials in this journal, and, while 
acknowledging that ‘it may well be difficult for cardiologists who are 
already hard pressed in providing cardiac assessments and investigations to 
consider spending more time on the issues covered in these editorials’, 
they pointed to the possible benefits, lying ‘in prevention of heart disease, 
routine clinical care, and the identification and treatment of disabling 
complications’.  
 Unfortunately, in the succeeding years, with the growth of rapid access 
chest pain clinics and much greater awareness of cardiac pathology 
fostered by the Internet,  psychological aspects have retreated a little, and 
it is likely that reluctance of both clinicians to offer psychological therapies 
and patients to accept them will increase unless there is a major change in 
thinking. Now that health anxiety and some other persisting types of 
anxiety have been shown to have adverse effects on cardiac outcome5-6 
there is a need for a new approach involving integration of psychological 
assessment and treatment in cardiac teams such as those introduced by 
Chambers et al31 to achieve better cardiac outcomes as well as addressing 
health care use in those with non-cardiac pain. 
This might mean that patients are recruited to such studies in primary 
rather than secondary care, as in the primary care setting there is less 
pressure on practitioners to be absolutely sure they have excluded physical 
disease.  Further studies in secondary care would be best focused on the 
group with the following inclusion criteria:- 
(a) persistent or recurrent chest pain over a period of at least 6 months, 
(b) repeated negative evidence of relevant physical pathology by 
examination and laboratory investigations (eg negative troponin 
tests), 
(c) psychological assessment by a combination of rating scales such as 
those used in this study11-15 as well as face-to-face assessment, to 
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confirm psychopathology of anxiety, depression and somatic 
symptomatology. 
Similar psychological assessments have been used in cancer services with 
good effect on outcomes.32     Better screening to firm up the exclusion of 
those with other psychopathology is probably needed also.   
 
Our findings, and the collective view of other studies, support 
comprehensively the notion that in secondary care, a multidisciplinary 
team including cardiologists, psychologist and nurses,  preferably linked to 
rapid access chest pain clinics, should become a stepped care standard33.  It 
is not going to be satisfactory to refer patients for psychological treatment 
unless the mental sets and attitudes of the referring agencies are able to 
impart to the patient the likely benefits of a different approach to 
management, and without a strong medical component other disorders 
such as oesophageal reflux may be wrongly referred for psychological 
input. In previous work we have found that general nurses can be highly 
effective in changing attitudes as well as providing treatment34 and when 
other members of the clinical team are all consistent in promoting biosocial 
alternatives for chest pain, adherence to treatment is likely to be much 
greater.  In the linked study in Christchurch, New Zealand, much greater 
levels of recruitment were achieved as the project was nicely encapsulated 
as a ‘healthy heart’ intervention; this neatly joins up psychological and 
physical aetiologies. 
 
What was also clear from the study was that the diagnosis of non-cardiac 
chest pain is a very unsatisfactory one as it is so heterogeneous,  and this 
heterogeneity was emphasized by recruitment from both accident and 
emergency clinics and cardiology ones. This problem cannot be overcome 
by a simple screening procedure such as a questionnaire as no instrument 
would be able to disentangle the different causes. This heterogeneity 
probably reduced the efficacy of CBT-CP in reducing symptoms but the 
benefits in terms of reduced outpatient,  inpatient and accident and 
emergency attendances,  were nonetheless substantial. It also suggests 
that more general measures than specific symptoms, such as quality of life 
measured perhaps in greater depth than the EQ-5D such as the SF-6D35, 
might be a better choice of primary outcome. With the current demands 
 16 
for financial savings on all publicly funded health services, the economic 
benefits of introducing such a service are very persuasive. Common sense 
suggests a multidisciplinary medico-psychological team is better able to 
carry out this assessment than any other, and a large proportion of patients 
will need only very limited input to make a good recovery.  The remainder 
could receive an intervention similar to CBT-CP to address the many 
complex factors that reinforce chest pain in vulnerable individuals. 
 
  
 
 
Conclusions 
 
The combination of limited clinical improvement, becoming amplified over 
time, together with possible economic gains,  suggest that CBT-CP could be  
a cost-effective treatment for non-cardiac chest pain,  but changes in 
service configuration, mental health literacy in hospitals, and a different 
recruitment strategy are necessary to achieve its maximum benefit.  An 
integrated service to assess both medical and mental pathology is 
considered necessary for progress to be made. 
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Table 1  baseline information 
Variable TAU(n=34) CBT(n=34) 
Age:mean(sd) 48.71 (13.46) 48.91 (14.50) 
Centre:n(%)   
Notts 14 (41.8) 14 (41.8) 
Hillingdon 7 (20.59) 6 (17.65) 
Berks 13 (38.24) 14 (41.18) 
gender:n(%)   
Male 24 (70.59) 23 (67.65) 
Female 10 (29.41) 11 (32.35) 
Ethnicity:n(%)   
White British 29 (85.29) 24 (70.59) 
Others 5 (14.71) 10 (29.41) 
HAI:mean(sd) 16.29 (8.45) 18.13 (8.50) 
HADS-Anx:mean(sd) 8.53 (4.81) 9.53 (4.43) 
HADS0Dep:mean(sd) 5.01 (3.71) 6.12 (4.26) 
SFQ:mean(sd) 4.56 (3.57) 5.16 (3.69) 
EQ5D:mean(sd) 7.79 (1.53) 7.03 (1.71) 
HAQCP:mean(sd) 19.97 (12.80) 23.13 (12.53) 
Pain frequency:mean(sd) 3.62 (1.46) 3.32 (1.87) 
Pain severity:mean(sd) 5.41 (2.28) 6.24 (2.44) 
SEPS symptoms:mean(sd) 5.79 (1.45) 5.85 (1.64) 
SEPS mean: (sd) 14.97 (4.27) 16.21 (5.15) 
 
No of patients HAI ≥20(%) 10 (29.41) 15(44.12) 
 
 
Table  2  results of multilevel modelling of change score (95% CI) from baseline 
and group difference (95% CI) 
 TAU (n=34) CBT (n=34) Group comparison  
 
Mean change from 
Baseline (95% CI)  
Mean change from 
 baseline (95% CI) 
Change difference 
 (95%CI) 
P value 
HAI*     
6 month -3.29(-5.63, -0.95) -2.35(-4.58, -0.12) 0.94(-2.30, 4.17) 0.569 
12 month -4.21(-6.73, -1.69) -4.97(-7.41, -2.54) -0.76(-4.11, 2.59) 0.654 
HADS_anx     
6 month -2.39(-3.80, -0.99) -2.99(-4.27, -1.71) -0.60(-2.55, 1.35) 0.546 
12 month -3.08(-4.49, -1.67) -4.15(-5.65, -2.66) -1.07(-3.19, 1.05) 0.319 
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HADS_dep     
6 month -0.69(-1.86, 0.48) -0.96(-2.15, 0.23) -0.27(-1.91, 1.38) 0.75 
12 month -1.57(-2.77, -0.38) -1.99(-3.23, -0.75) -0.41(-2.15, 1.32) 0.639 
SFQ     
6 month -0.75(-1.94, 0.43) -0.52(-1.64, 0.61) 0.24(-1.39, 1.86) 0.774 
12 month -0.22(-1.42, 0.98) -0.94(-2.17, 0.29) -0.72(-2.55, 1.11) 0.435 
HAQCP     
6 month -3.31(-6.48, -0.14) -5.75(-9.00, -2.50) -2.44(-7.21, 2.32) 0.313 
12 month -5.16(-8.67, -1.66) -9.53(-12.93, -6.12) -4.36(-9.60, 0.87) 0.101 
INSKIP pain     
6 month -1.08(-1.64, -0.52) -0.43(-0.97, 0.10) 0.65(-0.11, 1.40) 0.095 
12 month -1.47(-2.07, -0.88) -1.40(-1.99, -0.80) 0.08(-0.71, 0.87) 0.842 
INSKIP severity     
6 month -0.72(-5.73, 4.30) -4.00(-9.12, 1.12) -3.29(-10.57, 4.00) 0.376 
12 month -0.60(-5.60, 4.41) -4.39(-9.59, 0.82) -3.79(-11.07, 3.49) 0.307 
Seps1symp     
6 month -0.84(-1.66, -0.02) -0.38(-1.12, 0.37) 0.46(-0.63, 1.55) 0.407 
12 month -0.76(-1.51, 0.00) -1.03(-1.76, -0.30) -0.27(-1.30, 0.76) 0.605 
SEPS2 mean     
6 month -2.76(-4.69, -0.82) -2.93(-5.01, -0.85) -0.17(-2.83, 2.49) 0.898 
12 month -3.80(-5.85, -1.76) -4.69(-6.97, -2.41) -0.88(-3.94, 2.17) 0.568 
 
(HAI (Health Anxiety Inventory), HADS-A (Anxiety section of Hospital Anxiety and Depression Scale), HADS-
D (Depression section of Hospital Anxiety and Depression Scale), SFQ (Social Functioning Questionnaire), 
Pain measured in terms of frequency and severity by INSKIP scales), SEPS1 (frequency of main symptoms), 
SEPS2 (disability produced by main symptoms) 
* Sub-group analysis of the high vs low HAI group (in Table 1) showed no important differences between 
the four groups so identified and HAI scores were all lower at 12 months than at 6 months 
 
  
 
 
 
 
 
Standard (n=25) CBT-CP (n=25) 
 
Mean  (SD) Mean SD 
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Number of CBT 
sessions 
0.00 (0.00) 5.72 3.49 
Inpatient (nights) 3.20 7.16 1.12 3.05 
Outpatient 
(appointments) 
3.80 5.71 1.80 2.38 
Day case 
(procedures) 
0.12 0.33 0.32 0.69 
Accident and 
emergency 
(attendances) 
3.36 9.36 1.20 1.61 
Diagnostic tests 
(number) 
0.12 0.33 0.32 0.69 
Community health 
and social care 
services (number) 
6.40 17.03 3.76 6.64 
Table 3: Mean (SD) use of health care services by randomised group over 12 months 
follow-up 
 
 
Standard (n=25) CBT-CP (n=25) Difference* 95% CI, p-value 
 
Mean  (SD) Mean SD   
CBT intervention 0 0 480.48 293.52   
Hospital costs 3403.48 6912.63 1631.96 2299.02   
Community costs 236.47 687.18 109.69 195.72   
Cardiac and 
psychotropic drug 
costs 
44.75 96.37 87.20 137.60   
Total cost 3732.02 7346.85 2235.53 2434.86 
-315.19 (-2782.69 to 2152.31), 
0.798 
*Adjusted for baseline cost 
Table 4: Mean (SD) total cost (£) of service used over 12 months follow-up  
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Standard CBT Difference* 95% CI, p-value 
 
Mean  (SD) Mean (SD)   
Utility baseline 
(n=68) 
0.62 0.25 0.65 0.29   
Utility 6 months 
(n=56) 
0.78 0.21 0.76 0.20   
Utility 12 months 
(n=52) 
0.78 0.22 0.86 0.23   
QALY (n=52) 0.74 0.19 0.76 0.19 0.004 (-0.07 to 0.07), 0.900 
 
Table 5: EQ-5D utility score and QALYs over 12 months follow-up 
 
